At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 3, 2026 at 08:00 ET
Certara announced that its Simcyp® Simulator was used to support the FDA's acceptance of PBPK modeling in lieu of clinical studies for the approval of asciminib (Scemblix®), a first-in-class treatment for Chronic Myeloid Leukemia. This marks a significant regulatory validation of Certara's model-informed drug development technology, highlighting its ability to replace at least ten clinical pharmacology studies and streamline the NDA process.
- FDA accepted PBPK modeling via Certara's Simcyp Simulator in lieu of clinical studies for asciminib (Scemblix®) NDA approval.
- Modeling replaced at least ten dedicated clinical pharmacology studies.
- Asciminib is a first-in-class allosteric inhibitor for Chronic Myeloid Leukemia (CML).
- Simcyp's modeling supported dosing regimens and drug interaction profiles across diverse populations.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access